News

Treating refractory and metastatic lung cancer


 

AT THE ASCO ANNUAL MEETING 2013

CHICAGO Dr. Roy Herbst of Yale University discusses early results for MPDL3280A, a new PD-L1 antibody for the treatment of non-small cell lung cancer; he also gives his take on other exciting lung cancer data being presented at the annual meeting of the American Society of Clinical Oncology.

Recommended Reading

Genetics contribute to smoking habits of adolescents, adults
MDedge Internal Medicine
Groups seek to curb tobacco use in cancer patients
MDedge Internal Medicine
Lung cancer rates highest in West Virginia
MDedge Internal Medicine
Androgen deprivation decreases lung tumors in men with prostate cancer
MDedge Internal Medicine
Marijuana habit not linked to lung cancer
MDedge Internal Medicine
FDA approves first EGFR mutation companion diagnostic test for NSCLC
MDedge Internal Medicine
Cardiorespiratory fitness predicts cancer risk, outcomes in men
MDedge Internal Medicine
Standard-dose radiation bests high-dose radiation in advanced NSCLC
MDedge Internal Medicine
Real-world NLST results show CT scans find more early-stage lung cancers
MDedge Internal Medicine
CDC urges doctors to help patients quit smoking
MDedge Internal Medicine